Embark Psychedelic Therapy for Depression - Brennan, Bill (Psychologist, Consultant, Psychologist, Consultant, C; Belser, Alex (Psychologist, Psychologist)
46,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person is a clinical guide that explores the innovative use of psychedelic therapy in treating depression. The book presents the EMBARK psychedelic therapy model, a comprehensive and participant-centric approach that focuses on the whole person, not just their symptoms. It delves into the preparation, medicine, and integration phases of therapy, providing practical guidelines for practitioners.

Andere Kunden interessierten sich auch für
Produktbeschreibung
EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person is a clinical guide that explores the innovative use of psychedelic therapy in treating depression. The book presents the EMBARK psychedelic therapy model, a comprehensive and participant-centric approach that focuses on the whole person, not just their symptoms. It delves into the preparation, medicine, and integration phases of therapy, providing practical guidelines for practitioners.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Bill Brennan, PhD, is a psychologist in New York City who has served as a clinical advisor at Cybin, Inc. and Gilgamesh Pharmaceuticals. He is a co-creator of the EMBARK approach to psychedelic therapy and is a core faculty member in the EMBARK psychedelic facilitator training program. He has trained and supervised psychedelic facilitators in several studies and has been the lead author of several psychedelic treatment manuals. He currently serves as an advisory board member of New Yorkers for Mental Health Alternatives. Alex Belser, PhD, is a clinical scientist, psychologist, author, and leader in psychedelic research. As a Co-Investigator at Yale University, he is exploring psilocybin therapy to treat OCD. With a strong commitment to developing psychedelic therapies, he has conducted clinical trials investigating the potential of psilocybin, MDMA, ketamine, and DMT in addressing depression, anxiety, addiction, and PTSD. He co-founded the non-profit Nautilus Sanctuary and the New York University Psychedelic Research Group in 2006. He served as the Chief Clinical Officer at Cybin and Adelia Therapeutics. He is the co-editor of Queering Psychedelics: From Oppression to Liberation in Psychedelic Medicine (2022).